Sun Health and Power3 Medical to Present Results of NuroPro® Alzheimer's Blood Test Clinical Validation Trial

Business Wire, Nov 7, 2008

Dr. Marwan Sabbagh to Present the Phase I Clinical Results at the 61(st) Annual Meeting of the American Academy of Neurology in Seattle in April 25-May 1, 2009

HOUSTON -- Power3 Medical Products, Inc. (OTCBB:PWRM) (https://www.power3medical.com) announced today that Dr. Marwan Sabbagh, Chief Medical-Scientific Officer of Sun Health and Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3, have jointly submitted an abstract entitled "Development of a novel biomarker approach for detection of Alzheimer's disease" for presentation by Dr. Sabbagh to the 61st annual meeting of the American Academy of Neurology to take place in Seattle on April 25 - May 1, 2009. Power3 Medical is a leading biomedical company specializing in the development and commercialization of protein based diagnostic blood tests for the early detection of breast cancer and neurodegenerative diseases.

The clinical validation trial involves the testing of prospective (fresh) blood samples from 100 patients and controls (non-cognitively impaired) at the Cleo Roberts Center, Sun Health Research Institute, 10515 W. Santa Fe Dr, Sun City, AZ, 85351. It follows Power3's in-house discovery and identification of 59 blood serum protein biomarkers, blood test development and validation, and patent filings, employing retrospective (stored) blood serum samples from 115 Alzheimer's disease patients, and 75 age-matched normal controls. "It is critical to have the ability to diagnose Alzheimer's disease more accurately, earlier, and faster than currently available. If physicians can intervene earlier, before the patients suffer debilitation and irreversible damage, the drugs currently used to slow disease progression can be more effective. In addition, the ability to detect Alzheimer's disease processes early and monitor disease progression in the patients' blood will ultimately lead to more effective and personalized treatments," said Power3's Dr. Goldknopf.

"This study is promising. There is a lot of interest in developing biomarkers for detection of Alzheimer's disease. Such technology would have immediate clinical applicability," added Sun Health's Dr. Marwan Sabbagh.

"Power3 Medical is gratified that renowned Alzheimer's Neurologist Dr. Marwan Sabbagh and the prestigious Sun Health Research Institute have teamed with Power3 in the clinical validation trials of Alzheimer's disease," said Helen R. Park, Interim CEO of Power3. "The positive results of this Phase I trial to be reported at the meeting will go a long way to show that the clinical and scientific community recognizes the importance of our advancements in Alzheimer's disease diagnosis through blood-based testing. In addition, this is further validation of Power3's leadership position in advancing biomarkers and blood tests to provide for more effective diagnostics and targeted therapeutics for neurodegenerative diseases and breast cancer."

About Power3 Medical Products

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 expects to complete phase II and III clinical validation trials of its blood serum diagnostics for Alzheimer's disease, AD-NuroPro[R], in Q3 of 2009 followed by completion of filing with the FDA. Power3 anticipates offering the AD-NuroPro[R] test beginning in the US by the Q1 of 2010. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers the Company has discovered from a broad range of diseases as the basis of highly selective blood-based tests for breast cancer, ALS, Alzheimer's, and Parkinson's Diseases.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.